Tegsedi
inotersen · Akcea Therapeutics Ireland Limited
ORPHAN AUTHORISED IN THE EUWhat Tegsedi is used for
Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Tegsedi
- Active substance
- inotersen
- Disease area
- Amyloidosis
- Medicine group
- Other nervous system drugs
- ATC code
- N07
- Marketing authorisation holder
- Akcea Therapeutics Ireland Limited
- Authorised in the EU since
- 2018
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tegsedi used for?
Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).
What is the active substance in Tegsedi?
Tegsedi contains inotersen.
Who makes Tegsedi?
The EU marketing authorisation holder is Akcea Therapeutics Ireland Limited.
Is Tegsedi an orphan medicine?
Yes. Tegsedi is designated an orphan medicine in the EU, for a rare disease (Amyloidosis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU